A Dose-Ranging Study of Pegylated Interferon Alfa-2b and Ribavirin in Chronic Hepatitis C

Abuchowski, 1977, J Biol Chem, 252, 3578, 10.1016/S0021-9258(17)40291-2 Abuchowski, 1977, J Biol Chem, 252, 3582, 10.1016/S0021-9258(17)40292-4 He, 1999, Life Sci, 65, 355, 10.1016/S0024-3205(99)00257-X Katre, 1990, J Immunol, 144, 209, 10.4049/jimmunol.144.1.209 Wang, 1993, Cancer Res, 53, 4588 Berardi, 1996, Fundam Appl Toxicol, 30, 36 Glue, 1999, Hepatology, 30, 189a Talpaz, 1998, Blood, 92, 251a Davis, 1998, N Engl J Med, 339, 1493, 10.1056/NEJM199811193392102 McHutchison, 1998, N Engl J Med, 339, 1485, 10.1056/NEJM199811193392101 Poynard, 1998, Lancet, 352, 1426, 10.1016/S0140-6736(98)07124-4 . Pharmacokinetics 2nd ed. New York: Marcel Dekker. 1982; 409-417. Assessment of hematological effects of ribavirin in humans. In: , eds. Clinical Application of Ribavirin. New York: Academic Press. 1984; 79-92. Khakoo, 1998, Br J Clin Pharmacol, 46, 563, 10.1046/j.1365-2125.1998.00836.x Gotoh, 1999, J Interferon Cytokine Res, 19, 1117, 10.1089/107999099313055 Makino, 1996, Kiso To Rinsho, 30, 95 Buchwalder, 1998, (abstract PI-117) Clin Pharmacol Ther, 63, 166 Billard, 1986, Blood, 67, 821, 10.1182/blood.V67.3.821.821 Lau, 1986, J Clin Invest, 77, 1632, 10.1172/JCI112480 Dusheiko, 1996, J Hepatol, 25, 591, 10.1016/S0168-8278(96)80225-X